Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclohexane SCHEMBL1243556 | 1.00 | CYP1A2 (0.46) | CYP1A2USP2ALDH1A1LMNATSHR | |
| Cyclohexane SCHEMBL6664121 | 1.00 | CYP1A2 (0.46) | CYP1A2USP2ALDH1A1LMNATSHR | |
| Cyclohexane SCHEMBL4960596 | 1.00 | CYP1A2 (0.46) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL2612029 | 0.97 | ALDH1A1 (0.43) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL2168378 | 0.91 | ALDH1A1 (0.61) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL14448382 | 0.91 | ALDH1A1 (0.61) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL8267491 | 0.88 | ALDH1A1 (0.42) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL13863969 | 0.88 | CYP1A2 (0.57) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL13544799 | 0.86 | ALDH1A1 (0.41) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL12173742 | 0.86 | ALDH1A1 (0.67) | CYP1A2USP2ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803804-B2 | Substituted pyrazines for use in the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-09-28 | — | — | US | disclosed |
| US-7803804-B2 | Substituted pyrazines for use in the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-09-28 | — | — | US | disclosed |
| US-20080312217-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| US-20080312217-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| WO-2007071396-A2 | PYRAZINOYLGUANIDINE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| US-4548936-A | ANTICOAGULANTS, VASODILATORS, AND HYPOTENSIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312217-A1 | Organic Compounds | TRPA1, TRPV1, CHRM1 | CYP1A2 277/4885USP2 4183/4885ALDH1A1 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.